Piotr Ozieranski, PhD

To learn more about Conflict of Interest and R&D in pharmaceutical industry, see the following publications

  1. Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ : British Medical Journal. 2012;345:e4348. doi:10.1136/bmj.e4348.
  2. Busfield J. The moral economy of the pharmaceutical industry: Legitimising prices. Health. 2021/05/01 2019;25(3):271-287. doi:10.1177/1363459319879474
  3. Lazonick W, Hopkins M, Jacobson K, Sakinç ME, Tulum Ö. US pharma's financialized business model. Institute for New Economic Thinking Working Paper Series. 2017;(60)
  4. Busfield J. Documenting the financialisation of the pharmaceutical industry. Social Science & Medicine. 2020/08/01/ 2020;258:113096. doi:https://doi.org/10.1016/j.socscimed.2020.113096
  5. Ozieranski P, McKee M, King L. Pharmaceutical Lobbying under Postcommunism: Universal or Country-Specific Methods of Securing State Drug Reimbursment in Poland. Health Econ Pol'y & L. 2012;7:175.
  6. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews. 2017;(2)doi:10.1002/14651858.MR000033.pub3
  7. Lo B, Field MJ. Conflict of Interest in Medical Research, Education, and Practice. National Academic Press. https://www.nap.edu/catalog/12598/conflict-of-interest-in-medical-research-education-and-practice
  8. Mulinari S, Martinon L, Jachiet P-A, Ozieranski P. Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries. Health Policy. 2021/05/04/ 2021;doi:https://doi.org/10.1016/j.healthpol.2021.04.015